Table 1.
Baseline Characteristics*
| TETRACYCLINE ARM (n=31) | PLACEBO ARM (n=30) | P-VALUE | |
|---|---|---|---|
|
| |||
| AGE | |||
| Median in years (range) | 71 (40, 84) | 63 (49, 84) | 0.14 |
|
| |||
| GENDER | |||
| Female | 16 (52) | 7 (23) | 0.02 |
| Male | 15 (48) | 23 (76) | |
|
| |||
| FIRST-LINE CHEMOTHERAPY? | |||
| Yes | 11 (35) | 11 (37) | 0.92 |
| No | 20 (65) | 19 (63) | |
|
| |||
| EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITOR | |||
| Gefitinib | 3 (10) | 5 (17) | 0.60 |
| Cetuximab | 11 (35) | 12 (40) | |
| Other | 17 (55) | 13 (43) | |
|
| |||
| CORTICOSTEROID THERAPY? | |||
| Yes | 6 (20) | 6 (20) | 0.94 |
| No | 25 (80) | 25 (80) | |
|
| |||
| CANCER TYPE | |||
| Lung | 18(58) | 13 (43) | |
| Gastrointestinal | 7 (23) | 9 (30) | 0.52 |
| Other | 6 (19) | 8 (27) | |
|
| |||
| POTENTIALLY CURABLE MALIGNANCY? | |||
| Yes | 3 (10) | 3 (10) | 0.97 |
| No | 28 (90) | 27 (90) | |
*
Numbers in parentheses denote percentages unless otherwise noted.